CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
By Mike Cherney
SYDNEY--Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular events after a heart attack "did not meet its primary efficacy endpoint."
CSL said there are no plans for a regulatory filing but that the study's results would continue to be analyzed over the coming months. It said the study, which involved more than 18,000 patients in dozens of countries, was the most ambitious study in the company's history.
The company said CSL had excluded any financial contribution from CSL112 in its forward-looking statements, and that it doesn't expect any material financial impact following the end of the study.
CSL said it will discuss CSL112 at its half-year result on Tuesday.
Write to Mike Cherney at mike.cherney@wsj.com
(END) Dow Jones Newswires
February 11, 2024 16:46 ET (21:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks